Abstract: Backgrounds: Prostate cancer is the second highest cause of malignant tumors in men worldwide, extraperitoneal laparoscopic radical prostatectomy (ELRP) was widely used in the treatment of localized prostate cancer. This study explored the factors affecting the length of stay in patients after ELRP. Methods: We performed a retrospective analysis of the clinical data of 209 patients undergoing ELRP between January 2019 and December 2020. The multiple linear regression analysis model was used to analyze the factors that influenced hospital stay in patients after ELRP. Results: The median postoperative hospital stay was 9 days. Univariate regression analysis found that postoperative complications, the presence or absence of blood product transfusion, and postoperative indwelling catheter time were correlated to a postoperative hospital stay (P < 0.05). After adjusting for other variables, multivariate regression analysis found that a history of drinking, preoperative PSA value of 10-20 μg/L, postoperative complications of anastomotic leakage, and postoperative indwelling catheter time were independent risk factors related to delayed discharge (P < 0.05 ~ P < 0.0001). Conclusion: The length of hospital stay after ELRP was affected by many factors. Low-level preoperative PSA values, avoiding complications of anastomotic leakage, and timely removal of catheters have the potential to shorten the hospital stay after ELRP. The high-risk groups should regularly check the serum PSA value to optimize the utilization of medical resources, and physicians should strive to improve intraoperative surgical techniques, reduce postoperative complications, and remove catheters in time.Abstract: Backgrounds: Prostate cancer is the second highest cause of malignant tumors in men worldwide, extraperitoneal laparoscopic radical prostatectomy (ELRP) was widely used in the treatment of localized prostate cancer. This study explored the factors affecting the length of stay in patients after ELRP. Methods: We performed a retrospective analysis of...Show More
Mayte Lima Pérez,Jorge Luis Soriano García,Jorge Luis Soriano-Lorenzo,Vilma Fleites Calvo,Masiel González Meisozo,Dunia Morales Morgado,Raidel Rodríguez Barrios,Carlos Domínguez Álvarez
Issue:
Volume 10, Issue 3, September 2022
Pages:
31-37
Received:
11 October 2022
Accepted:
7 November 2022
Published:
16 November 2022
DOI:
10.11648/j.jctr.20221003.12
Downloads:
Views:
Abstract: Background: Esophageal cancer is the sixth leading cause of cancer-related death worldwide. Despite the advances in the surgical approach, chemotherapy and radiotherapy regimens, and the continuous development of biological agents, survival outcomes for these patients remain low. The identification of new biomarkers capable of predicting worse survival regardless of the clinical stage is necessary. Purpose: The aim of this study is to evaluate the association between Prognostic Nutritional Index (PNI) and overall survival in patients with advanced squamous esophageal carcinoma. Methods: A retrospective and observational study was conducted in patients with diagnosis of advanced esophageal squamous cell carcinoma treated at Hermanos Ameijeiras Hospital from January 2013 to June 2019. The PNI was calculated using the following formula: 10 x Albumin (g/dL) + 0.005 x Lymphocyte counts (x109). Results: A total of 94 patients were enrolled in this study. The area under the curve (AUC) was 0,583 and the optimal cut-off value was 40. PNI was significantly associated with hemoglobin level, platelet count, total lymphocyte count, neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), and therapeutic response. PNI was negatively correlated with inflammatory indexes. Patients with PNI ˂40 had a significantly shorter median overall survival compared to patients with PNI ≥40. Multivariate analysis identified that ECOG ≥1, platelet count, NLR≥4 and PNI˂40 were independent prognostic factors for poor overall survival. Conclusion: The present study demonstrated that pretreatment PNI is a useful marker for predicting survival outcome in patients with advanced esophageal squamous cell carcinoma.Abstract: Background: Esophageal cancer is the sixth leading cause of cancer-related death worldwide. Despite the advances in the surgical approach, chemotherapy and radiotherapy regimens, and the continuous development of biological agents, survival outcomes for these patients remain low. The identification of new biomarkers capable of predicting worse surv...Show More
